Combination of Recombinant Bacterial ACE2 Receptors -Like Enzyme of B38-CAP and Isotretinoin Could be Promising Treatment for COVID-19 Infection- and Its Inflammatory Complications
Clinical trial NCT04382950 · UNKNOWN
Trial details
- NCT number
- NCT04382950
- Sponsor
- Kafrelsheikh University
- Status
- UNKNOWN
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2021-07-01
- Primary completion
- 2021-08-01
- Enrollment
- 24
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.